InvestorsHub Logo
icon url

fbg0316

10/23/16 7:54 AM

#7521 RE: CATTDOGG12347 #7520

Good points Cattdogg. When I bring up the issue, I am not trying to bash but really think the CEO's treatment of management compensation and dilution should be rationally questioned. Here we are three years after DO took the helm and referenced to shareholders in conversation "$50 stock price in two years" and the stock is currently below both the average price long-term shareholders came in under Tom Moore and under the average share price of around $12 that DO's investors have come in by way of all the offerings. Some of the things DO has done have arguably been blatantly and unethically damaging to shareholder interest (e.g., the 40% discounted secondary offering to push through and unprecedented increase in non-performance based bonus compensation) while others have weighed on the stock over time (e.g., ongoing dilution coupled with weak deals, such as the Knight Canada deal). While I'm very encouraged by the progress the company has made, it's disappointing that the stock price has not reflected shareholder value added, while management's ownership has increased. When management has shown it places a higher priority on siphoning shareholder assets to its own financial gain over generated a return on shareholders assets, it begs the if the scenario presented itself would we better better off selling the company outright now for say $30 than waiting to build more value for a higher price later (when in reality that higher market value down the road, if the same pace of dilution continues, could equate to a stock price that is not much higher but the real benefit of the added time is that it gives management more times to issues themselves more bonus shares to ensure the added time is accretive to themselves, not necessarily shareholders).
icon url

bill_y

10/23/16 9:23 AM

#7523 RE: CATTDOGG12347 #7520

fbg cattdog I understand the sentiment..this thing has been such a roller coaster for so long now..and after the amgen deal..well I thought thats it..no more eztreme downside..well guess I was wrong again..deliverance is a ways off no doubt..But then I remember I have managed to increase my holding here by 70% during a time where risk of long term ownership has been abated by clinical data and product expansion..I don't blame the management or the minor dilutions that have occurred since the big 1/125 awhile back.for recent fall out in the price...though I do not doubt management has benefited from it..I believe we will see 30.00 a share on its way to a bigger evaluation at some point in time..though I wonder some days if that will ever be the case given the nature of stock ownership here and the status of this little bio..as such a big advance forward..but still keeping the faith..and still believing patience and adding when money and opportunity present itself together is still the best course.